Form 8-K - Current report:
SEC Accession No. 0001790340-25-000059
Filing Date
2025-05-05
Accepted
2025-05-05 16:17:28
Documents
15
Period of Report
2025-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imrx-20250505.htm   iXBRL 8-K 24908
2 EX-99.1 imrx-20250505xexx991.htm EX-99.1 80402
6 imlogoa.jpg GRAPHIC 6512
  Complete submission text file 0001790340-25-000059.txt   255678

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imrx-20250505.xsd EX-101.SCH 1807
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imrx-20250505_lab.xml EX-101.LAB 23705
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imrx-20250505_pre.xml EX-101.PRE 13601
17 EXTRACTED XBRL INSTANCE DOCUMENT imrx-20250505_htm.xml XML 2922
Mailing Address 245 MAIN STREET, SECOND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, SECOND FLOOR CAMBRIDGE MA 02142 617-500-8080
Immuneering Corp (Filer) CIK: 0001790340 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40675 | Film No.: 25913211
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)